185 related articles for article (PubMed ID: 11917290)
1. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
Ben-Josef E; Han S; Tobi M; Vargas BJ; Stamos B; Kelly L; Biggar S; Kaplan I
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):81-5. PubMed ID: 11917290
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.
Ben-Josef E; Han S; Tobi M; Shaw LM; Bonner HS; Vargas BJ; Prokop S; Stamos B; Kelly L; Biggar S; Kaplan I
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1160-4. PubMed ID: 12128116
[TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
[TBL] [Abstract][Full Text] [Related]
4. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
Singh AK; Ménard C; Guion P; Simone NL; Smith S; Crouse NS; Godette DJ; Cooley-Zgela T; Sciuto LC; Coleman J; Pinto P; Albert PS; Camphausen K; Coleman CN
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1008-13. PubMed ID: 16730138
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
[TBL] [Abstract][Full Text] [Related]
6. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
Simone NL; Ménard C; Soule BP; Albert PS; Guion P; Smith S; Godette D; Crouse NS; Sciuto LC; Cooley-Zgela T; Camphausen K; Coleman CN; Singh AK
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):90-5. PubMed ID: 17855015
[TBL] [Abstract][Full Text] [Related]
7. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
[TBL] [Abstract][Full Text] [Related]
8. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?
Kupelian PA; Reddy CA; Carlson TP; Willoughby TR
Cancer J; 2002; 8(1):62-6. PubMed ID: 11895204
[TBL] [Abstract][Full Text] [Related]
9. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect.
Lee WR; Hanks GE; Hanlon AL; Schultheiss TE; Hunt MA
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):251-7. PubMed ID: 8635930
[TBL] [Abstract][Full Text] [Related]
10. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
[TBL] [Abstract][Full Text] [Related]
11. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
Muanza TM; Albert PS; Smith S; Godette D; Crouse NS; Cooley-Zgela T; Sciuto L; Camphausen K; Coleman CN; Ménard C
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1316-21. PubMed ID: 16029787
[TBL] [Abstract][Full Text] [Related]
12. Topical application of WR-2721 achieves high concentrations in the rectal wall.
Ben-Josef E; Mesina J; Shaw LM; Bonner HS; Shamsa F; Porter AT
Radiat Res; 1995 Jul; 143(1):107-10. PubMed ID: 7597137
[TBL] [Abstract][Full Text] [Related]
13. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
Dunst J; Semlin S; Pigorsch S; Müller AC; Reese T
Strahlenther Onkol; 2000 Sep; 176(9):416-21. PubMed ID: 11050915
[TBL] [Abstract][Full Text] [Related]
14. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
[TBL] [Abstract][Full Text] [Related]
15. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
16. Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Myerson R
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):86-90. PubMed ID: 11917291
[TBL] [Abstract][Full Text] [Related]
17. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
[TBL] [Abstract][Full Text] [Related]
18. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients.
Prada PJ; Fernández J; Martinez AA; de la Rúa A; Gonzalez JM; Fernandez JM; Juan G
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):95-102. PubMed ID: 17707267
[TBL] [Abstract][Full Text] [Related]
19. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
[TBL] [Abstract][Full Text] [Related]
20. Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy: phase I/II randomized placebo-controlled trial.
Razzaghdoust A; Mozdarani H; Mofid B
Strahlenther Onkol; 2014 Aug; 190(8):739-44. PubMed ID: 24619016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
